Donor insulin use during stay in the intensive care unit should not preclude pancreas transplantation. Reply to Ventura-Aguiar P, Montagud-Marrahi E, Amor AJ et al [letter].
Donor insulin use during stay in the intensive care unit should not preclude pancreas transplantation. Reply to Ventura-Aguiar P, Montagud-Marrahi E, Amor AJ et al [letter].
复制标题
在重症监护病房期间使用捐赠者胰岛素不应妨碍胰腺移植。
DOI：
10.1007/s00125-021-05502-7
复制
发表时间：
2021
期刊：
影响因子：
8.2
通讯作者：
Shapey IM
中科院分区：
文献类型：
--
作者：
Shapey IM
致编辑：我们欢迎Ventura-Aguiar等人[1]关于我们最近在Diabetologia [2]上发表的文章的通信，并珍惜回应的机会。Ventura-Aguiar等人评论了脑死亡相关供体高血糖症发病机制的不确定性[1]，目前缺乏相关和可靠的数据[3]。我们完全同意他们关于循环microRNA和游离DNA的潜在作用的建议，以澄清不可逆的β细胞死亡和可逆的胰岛素抵抗（应激性高血糖症）对供体胰腺功能的各自影响。虽然我们之前已经报道了无细胞DNA数据在胰腺移植中的潜在应用[4]，并公开展示了与此相关的一些microRNA [5]数据，但我们期待在不久的将来与学术界分享我们完整的生物标志物数据。
To the Editor: We welcome the correspondence from Ventura-Aguiar et al [1] regarding our recent publication in Diabetologia [2] and value the opportunity to respond. Ventura-Aguiar et al commented on the uncertainties relating to the pathogenesis of brain-death-related donor hyperglycaemia [1], for which there is currently a paucity of relevant and robust data [3]. We totally agree with their suggestion of a potential role of circulating microRNA and cell-free DNA to clarify the respective impact of irreversible beta cell death and reversible insulin resistance (stress hyperglycaemia) on donor pancreas function. Whilst we have previously reported the potential application of cell-free DNA data to pancreas transplantation [4] and have publicly presented some of our microRNA [5] data in relation to this, we look forward to sharing our complete biomarker data with the academic community in the near future.